Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
| Revenue (TTM) | $413.80M |
| Gross Profit (TTM) | $-10.58M |
| EBITDA | $-101.55M |
| Operating Margin | -89.60% |
| Return on Equity | -898.00% |
| Return on Assets | -6.51% |
| Revenue/Share (TTM) | $2.54 |
| Book Value | $-1.16 |
| Price-to-Book | 33.20 |
| Price-to-Sales (TTM) | 4.07 |
| EV/Revenue | 3.102 |
| EV/EBITDA | 1.72 |
| Quarterly Earnings Growth (YoY) | -38.10% |
| Quarterly Revenue Growth (YoY) | -76.30% |
| Shares Outstanding | $164.95M |
| Float | $142.53M |
| % Insiders | 5.06% |
| % Institutions | 68.95% |
Volatility is currently expanding
GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, New YorkFireside chat on Wednesday, September 9, 2026, at 9:45 a.m.
Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday trading.
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients GAITHERSBURG, Md., Aug. 28, 2026 /PRNewswire/ -- Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan.
Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs.
Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.
Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform and continued cost reductions.
Novavax (NVAX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to earnings of $0.62 per share a year ago.
Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Novavax raised its annual revenue forecast after beating quarterly expectations on Thursday, as the vaccine maker's licensing-driven milestone payments helped offset waning demand.
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax Multiple partner-led experiments with Matrix-M are currently underway in a wide array of infectious disease and oncology targets On track to advance C. difficile vaccine program into the clinic as early as 2027 GAITHERSBURG, Md.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVAX and any ticker you trade — then tracks every position and per-strategy win rate.
